Neuropsychological test performance in healthy volunteers before and after donepezil administration

Leigh J. Beglinger, Brenda L. Gaydos, David Kareken, Oranee Tangphao-Daniels, Eric R. Siemers, Richard C. Mohs

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Participants in early Phase I clinical trials for drugs designed to enhance cognition are typically healthy volunteers. If improvement can be detected with a battery of cognitive tests in healthy volunteers, such a battery could be a pharmacodynamic marker in the future development of the compound for treatment of cognitive disorders. In the present exploratory study, a battery of neuropsychological (NP) tests was used to determine if changes in cognition from a pharmacological intervention could be detected in healthy volunteers. A drug with known cognitive-enhancing effects in Alzheimer's disease, donepezil, was compared with placebo and no treatment arms. Carry-over effects of repeated test administration were also assessed. In this double-blind study, 27 healthy adults were randomized into one of three arms (eight donepezil, nine placebo and 10 no treatment) and completed 14 days of donepezil (5 mg q.h.s.) or placebo (q.h.s.). A battery of NP tests was administered on days 0, 7, 14 (randomization), 21, 28 (end of treatment) and 42 (washout). There were no differences in performance between the placebo and the no treatment arms. However, on day 21, subjects in the donepezil group performed slightly but significantly worse on some tests of speed, attention and memory (p < 0.05) compared to the pooled control group (placebo and no treatment arms). No improvement in performance was present while on donepezil at days 21 or 28. While the results are counter to expectations, some tests in the battery did detect a cognitive change (transient mild worsening during drug administration) in healthy volunteers.

Original languageEnglish
Pages (from-to)102-108
Number of pages7
JournalJournal of Psychopharmacology
Volume18
Issue number1
DOIs
StatePublished - Mar 2004

Fingerprint

Neuropsychological Tests
Healthy Volunteers
Placebos
Cognition
Therapeutics
Pharmaceutical Preparations
Clinical Trials, Phase I
Random Allocation
Double-Blind Method
donepezil
Alzheimer Disease
Pharmacology
Control Groups

Keywords

  • Clinical trials
  • Cognition
  • Donepezil
  • Learning
  • Memory
  • Phase I

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health
  • Neuroscience(all)

Cite this

Neuropsychological test performance in healthy volunteers before and after donepezil administration. / Beglinger, Leigh J.; Gaydos, Brenda L.; Kareken, David; Tangphao-Daniels, Oranee; Siemers, Eric R.; Mohs, Richard C.

In: Journal of Psychopharmacology, Vol. 18, No. 1, 03.2004, p. 102-108.

Research output: Contribution to journalArticle

Beglinger, Leigh J. ; Gaydos, Brenda L. ; Kareken, David ; Tangphao-Daniels, Oranee ; Siemers, Eric R. ; Mohs, Richard C. / Neuropsychological test performance in healthy volunteers before and after donepezil administration. In: Journal of Psychopharmacology. 2004 ; Vol. 18, No. 1. pp. 102-108.
@article{6d7fd2411e684af8a81baeca2cde39f2,
title = "Neuropsychological test performance in healthy volunteers before and after donepezil administration",
abstract = "Participants in early Phase I clinical trials for drugs designed to enhance cognition are typically healthy volunteers. If improvement can be detected with a battery of cognitive tests in healthy volunteers, such a battery could be a pharmacodynamic marker in the future development of the compound for treatment of cognitive disorders. In the present exploratory study, a battery of neuropsychological (NP) tests was used to determine if changes in cognition from a pharmacological intervention could be detected in healthy volunteers. A drug with known cognitive-enhancing effects in Alzheimer's disease, donepezil, was compared with placebo and no treatment arms. Carry-over effects of repeated test administration were also assessed. In this double-blind study, 27 healthy adults were randomized into one of three arms (eight donepezil, nine placebo and 10 no treatment) and completed 14 days of donepezil (5 mg q.h.s.) or placebo (q.h.s.). A battery of NP tests was administered on days 0, 7, 14 (randomization), 21, 28 (end of treatment) and 42 (washout). There were no differences in performance between the placebo and the no treatment arms. However, on day 21, subjects in the donepezil group performed slightly but significantly worse on some tests of speed, attention and memory (p < 0.05) compared to the pooled control group (placebo and no treatment arms). No improvement in performance was present while on donepezil at days 21 or 28. While the results are counter to expectations, some tests in the battery did detect a cognitive change (transient mild worsening during drug administration) in healthy volunteers.",
keywords = "Clinical trials, Cognition, Donepezil, Learning, Memory, Phase I",
author = "Beglinger, {Leigh J.} and Gaydos, {Brenda L.} and David Kareken and Oranee Tangphao-Daniels and Siemers, {Eric R.} and Mohs, {Richard C.}",
year = "2004",
month = "3",
doi = "10.1177/0269881104040248",
language = "English",
volume = "18",
pages = "102--108",
journal = "Journal of Psychopharmacology",
issn = "0269-8811",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Neuropsychological test performance in healthy volunteers before and after donepezil administration

AU - Beglinger, Leigh J.

AU - Gaydos, Brenda L.

AU - Kareken, David

AU - Tangphao-Daniels, Oranee

AU - Siemers, Eric R.

AU - Mohs, Richard C.

PY - 2004/3

Y1 - 2004/3

N2 - Participants in early Phase I clinical trials for drugs designed to enhance cognition are typically healthy volunteers. If improvement can be detected with a battery of cognitive tests in healthy volunteers, such a battery could be a pharmacodynamic marker in the future development of the compound for treatment of cognitive disorders. In the present exploratory study, a battery of neuropsychological (NP) tests was used to determine if changes in cognition from a pharmacological intervention could be detected in healthy volunteers. A drug with known cognitive-enhancing effects in Alzheimer's disease, donepezil, was compared with placebo and no treatment arms. Carry-over effects of repeated test administration were also assessed. In this double-blind study, 27 healthy adults were randomized into one of three arms (eight donepezil, nine placebo and 10 no treatment) and completed 14 days of donepezil (5 mg q.h.s.) or placebo (q.h.s.). A battery of NP tests was administered on days 0, 7, 14 (randomization), 21, 28 (end of treatment) and 42 (washout). There were no differences in performance between the placebo and the no treatment arms. However, on day 21, subjects in the donepezil group performed slightly but significantly worse on some tests of speed, attention and memory (p < 0.05) compared to the pooled control group (placebo and no treatment arms). No improvement in performance was present while on donepezil at days 21 or 28. While the results are counter to expectations, some tests in the battery did detect a cognitive change (transient mild worsening during drug administration) in healthy volunteers.

AB - Participants in early Phase I clinical trials for drugs designed to enhance cognition are typically healthy volunteers. If improvement can be detected with a battery of cognitive tests in healthy volunteers, such a battery could be a pharmacodynamic marker in the future development of the compound for treatment of cognitive disorders. In the present exploratory study, a battery of neuropsychological (NP) tests was used to determine if changes in cognition from a pharmacological intervention could be detected in healthy volunteers. A drug with known cognitive-enhancing effects in Alzheimer's disease, donepezil, was compared with placebo and no treatment arms. Carry-over effects of repeated test administration were also assessed. In this double-blind study, 27 healthy adults were randomized into one of three arms (eight donepezil, nine placebo and 10 no treatment) and completed 14 days of donepezil (5 mg q.h.s.) or placebo (q.h.s.). A battery of NP tests was administered on days 0, 7, 14 (randomization), 21, 28 (end of treatment) and 42 (washout). There were no differences in performance between the placebo and the no treatment arms. However, on day 21, subjects in the donepezil group performed slightly but significantly worse on some tests of speed, attention and memory (p < 0.05) compared to the pooled control group (placebo and no treatment arms). No improvement in performance was present while on donepezil at days 21 or 28. While the results are counter to expectations, some tests in the battery did detect a cognitive change (transient mild worsening during drug administration) in healthy volunteers.

KW - Clinical trials

KW - Cognition

KW - Donepezil

KW - Learning

KW - Memory

KW - Phase I

UR - http://www.scopus.com/inward/record.url?scp=2442555238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442555238&partnerID=8YFLogxK

U2 - 10.1177/0269881104040248

DO - 10.1177/0269881104040248

M3 - Article

C2 - 15107192

AN - SCOPUS:2442555238

VL - 18

SP - 102

EP - 108

JO - Journal of Psychopharmacology

JF - Journal of Psychopharmacology

SN - 0269-8811

IS - 1

ER -